These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21744260)

  • 1. Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD.
    Van Buren P; Velez RL; Vaziri ND; Zhou XJ
    Int Urol Nephrol; 2012 Apr; 44(2):499-507. PubMed ID: 21744260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis.
    Vaziri ND
    Am J Kidney Dis; 2013 Jun; 61(6):992-1000. PubMed ID: 23375852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Issues in Iron Treatment in CKD.
    Vaziri ND
    Semin Nephrol; 2016 Mar; 36(2):112-8. PubMed ID: 27236132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pumping iron: revisiting risks, benefits and strategies in treatment of iron deficiency in end-stage renal disease.
    Singh N; Agarwal AK
    Clin Nephrol; 2012 Mar; 77(3):188-94. PubMed ID: 22377249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iron therapy in renal failure: friend and foe?
    Afzali B; Goldsmith DJ
    J Nephrol; 2004; 17(4):487-95. PubMed ID: 15372409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron toxicity: relevance for dialysis patients.
    Fishbane S; Mathew A; Vaziri ND
    Nephrol Dial Transplant; 2014 Feb; 29(2):255-9. PubMed ID: 24166458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
    Singh A
    Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron and infection in hemodialysis patients.
    Ishida JH; Johansen KL
    Semin Dial; 2014; 27(1):26-36. PubMed ID: 24329610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis.
    Susantitaphong P; Alqahtani F; Jaber BL
    Am J Nephrol; 2014; 39(2):130-41. PubMed ID: 24513913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
    Rottembourg J; Rostoker G
    Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A; Bhandari S
    Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron therapy in end-stage renal disease.
    Brewster UC
    Semin Dial; 2006; 19(4):285-90. PubMed ID: 16893405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron therapy for renal anemia: how much needed, how much harmful?
    Hörl WH
    Pediatr Nephrol; 2007 Apr; 22(4):480-9. PubMed ID: 17206511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
    Albaramki J; Hodson EM; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007857. PubMed ID: 22258974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Erythropoetin and iron preparations in the treatment of anemia in patients with chronic kidney disease of stage III-IV in systemic diseases].
    Kozlovskaia LV; Milovanov IuS; Nikolaev AIu; Milovanova LIu
    Ter Arkh; 2007; 79(6):30-4. PubMed ID: 17684963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When should iron supplementation in dialysis patients be avoided, minimized or withdrawn?
    Rostoker G
    Semin Dial; 2019 Jan; 32(1):22-29. PubMed ID: 29956370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
    Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does iron cause bacterial infections in patients with end stage renal disease?
    Cieri E
    ANNA J; 1999 Dec; 26(6):591-6. PubMed ID: 10876474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of renal anemia in patients with chronic kidney disease: the role of the general practitioner].
    Ruedin P; Dickenmann M; Martin PY; Wüthrich RP
    Rev Med Suisse; 2012 Jan; 8(323):70-3. PubMed ID: 22303745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic effects of IV iron preparations in CKD patients.
    Vaziri ND
    Nephrol News Issues; 2014 Feb; 28(2):4-5. PubMed ID: 24649744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.